![]() | Up a level |
Zaitceva, V, Tan, I, Mills, M. and Kanavos, P. ORCID: 0000-0001-9518-3089
(2024)
HPR253 Drug development and launch timeline analysis across 6 high-income countries: from pivotal trial to HTA.
Value in Health, 27 (12, Supplement).
S323 - S323.
ISSN 1098-3015
Eaves, K., Lin, R., Alani, A. H. ORCID: 0000-0001-6318-3017, Mills, M. and Kanavos, P.
ORCID: 0000-0001-9518-3089
(2024)
HTA117 Sentiment analysis of clinical evaluations in HTA: evidence from Canada, England, Scotland, Sweden, France, and Germany.
Value in Health, 27 (12, Supplement).
S376 - S376.
ISSN 1098-3015
Eaves, K., Lin, R., Mills, M. and Kanavos, Panos ORCID: 0000-0001-9518-3089
(2024)
HTA201 A quantitative assessment of the economic decision drivers outlined in HTA outcomes through stratification and sentiment analysis: evidence from Canada, England, Scotland, and Sweden.
Value in Health, 27 (12 Supplement).
S393 - S393.
ISSN 1098-3015
Tolkmitt, F., Chavez, D., Mills, M. and Kanavos, P. ORCID: 0000-0001-9518-3089
(2024)
HTA354 Determinants of added benefit ratings in Germany: an econometric analysis of assessments from the Federal Joint Committee between 2012 and 2024.
Value in Health, 27 (12 Supplement).
S425 - S425.
ISSN 1098-3015
Lin, R., Eaves, K., Mills, M. and Kanavos, P. ORCID: 0000-0001-9518-3089
(2024)
HTA64 Leveraging machine learning for predicting health technology assessment outcomes.
Value in Health, 27 (12, Supplement).
S365 - S365.
ISSN 1098-3015
Chavez, D., Tolkmitt, F., Mills, M. and Kanavos, P. ORCID: 0000-0001-9518-3089
(2024)
PT7 Reassessment dynamics of orphan drugs in Germany's benefit assessment process.
Value in Health, 27 (12, Supplement).
S323 - S323.
ISSN 1098-3015